Abstract

One histopathological characteristic of intracranial germinoma is abundant tumor-infiltrating lymphocytes (TILs) showing a two-cell pattern with large undifferentiated tumor cells. The programmed cell death 1 (PD-1)/programmed cell death 1 ligand (PD-L) axis has recently been recognized as an anti-tumor immune system. To evaluate intratumor immune status in intracranial germinoma, we examined expressions of PD-1 and PD-L1 (clone 28–8) and subtypes of TILs. Expressions of PD-1 and PD-L1 were detected immunohistochemically in 25 formalin-fixed, paraffin-embedded tumor specimens from 24 patients with intracranial germinoma consisting of 22 primary and 3 recurrent tumors. To evaluate subtypes of TILs, quantification of lymphocytes with CD3, CD8, CD4, and Foxp3 was performed. Statistical analyses were performed among PD-1, PD-L1 and subtypes of TILs. In 25 tumor tissue, expressions of PD-1 in TILs and PD-L1 in tumor cells were identified in 96% (24/25) and 92% (23/25), respectively. Expression of PD-1 was associated with CD3+ TIL density. Expression of PD-1 correlated with Foxp3+ TIL density and CD8+ TIL density, but not with CD4+ TIL density. Furthermore, expression of PD-1 correlated strongly with Foxp3+/CD4+ ratio. Taken together, increase of PD-1+ expression is associated with accumulation of Foxp3+ and CD8+ TILs. These findings intimate that PD-1/PD-L1 axis might shape the immune infiltration suggesting a modulation of the immune response and subsequent tumor growth in intracranial germinoma. Anti-PD-1 and anti-PD-L1 are potential immune therapeutic strategies in intracranial germinoma.

Highlights

  • Central nervous system (CNS) germ cell tumors (GCTs) are common in Asia, where they account for 8–15% of all CNS tumors of childhood, compared to 3–4% in the United States [1,2,3]

  • We found prominent programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) expressions to variable extents in primary intracranial germinoma tissues

  • In 25 tumor tissues, including all recurrent samples, expression of PD-1 in tumor-infiltrating lymphocytes (TILs) was identified in 96% (24/25) and PD-L1 in tumor cells was identified in 92% (23/25)

Read more

Summary

Introduction

Central nervous system (CNS) germ cell tumors (GCTs) are common in Asia, where they account for 8–15% of all CNS tumors of childhood, compared to 3–4% in the United States [1,2,3]. Pharmaceutical, Nihon Medi-Physics, Astellas Pharma, Daiichi Sankyo, Chugai Pharmaceutical, Eisai, Meiji Seika Pharma, Otsuka Pharmaceutical, Nihon Medi-Physics, Siemens, Philips, Sanofi, Mitsubishi Tanabe Pharma, CSL Behring, Takeda Pharmaceutical, HOYA Technosurgical, Carl Zeiss and Brainlab AG. Yoshiki Arakawa has honoraria from Chugai Pharmaceutical, Eisai, Merck, Meiji Seika Pharma, Daiichi Sankyo, Otsuka Pharmaceutical, CSL Behring, Novocure, Takeda Pharmaceutical, Nippon Kayaku and Brainlab AG. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials. All other authors have declared that no other competing interests exist

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call